Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$41.59 USD
-0.25 (-0.60%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $41.60 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IONS 41.59 -0.25(-0.60%)
Will IONS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IONS
Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?
Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound?
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y
Ionis Pharmaceuticals (IONS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Other News for IONS
Piper Sandler Remains a Buy on Ionis Pharmaceuticals (IONS)
IN BRIEF: BB Biotech swings to profit in quarter as asset value rises
Ionis Publishes 2023 Corporate Responsibility Report
Ionis to hold first quarter 2024 financial results webcast
Hepion ends Phase 2 study for NASH drug due to cash restraints